secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093855
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q2 net loss widens to $1.31/share; cash rises to $1.4B on $563M offering and $250M Royalty Pharma deal
--------------------------------------------------------------------------------

- Net loss of $143.3M ($1.31/share) vs $128.6M ($1.34/share) in Q2 2023; revenue down to $0.2M from $0.9M.
- Cash & investments $1.4B as of June 30, 2024, up from $634.3M at March 31, aided by $563.2M public offering and $250M upfront from Royalty Pharma.
- Rolling NDA for aficamten underway; Type B meeting with FDA held on risk mitigation; submission on track for Q3 2024.
- FDA cleared FOREST-HCM protocol amendment reducing echo monitoring frequency for obstructive HCM patients.
- Updated 2024 GAAP OpEx guidance raised to $555M-$575M (prev $535M-$555M); net cash use unchanged at $400M-$420M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024093855/0000950170-24-093855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024093855/cytk-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer